An anti-hair loss treatment in the management of mild androgenetic alopecia: results from a large, international observational study.

Introduction Androgenic alopecia (AGA) is a common and chronic condition. It may impact self-esteem, self-image and quality of life. Benefit, tolerability, cosmetic acceptance and patient satisfaction are key to ensuring good treatment outcome. Aim Assessment of hair loss improvement and hair quality with AC5 in subjects with mild AGA in real life settings. Materials and methods Open-label, observational, international real-life study in 527 adult subjects with mild AGA who received AC5 (2,4-Diamino-Pyrimidine-N-Oxyde, arginine, 6-O glucose linoleate (SP94), piroctone olamine and Vichy mineralizing water) once daily for 3 months. After 3 months, investigators evaluated the impact of AC5 on hair loss and product satisfaction, and asked subjects about local tolerance; subjects assessed hair growth and quality, as well as satisfaction. Results Data from 357 subjects were evaluable for the benefit analysis; 59.9% of subjects were female; the mean age was 33.6±8.7 years. Duration of hair loss was 1.62±2.24 years. 71.3% of women had a Ludwig score of 1 and 40.8% of men had a Hamilton Norwood score of 2. At the end of study, hair loss was reduced in 89.0% of subjects; it was slightly higher in women (92.5%) than in men (83.8%). Subject satisfaction on a scale from 0 (not satisfied at all) to 10 (completely satisfied) was 7.9±1.7. Tolerance was rated good to very good by 98.6% of all subjects. Conclusion AC5 reduces mild AGA in both men and women and has a pleasant texture. AC5 was well tolerated and highly appreciated. This article is protected by copyright. All rights reserved.